AI Article Synopsis
- Invasive fungal infections (IFIs) are particularly challenging for hospitalized and immunocompromised children, leading to high rates of illness and death despite better diagnostics and treatments.
- The introduction of new antifungal agents and oral formulations offers improved prevention and treatment options, although their effectiveness in severely immunosuppressed patients has not yet been thoroughly researched.
- Implementing specialized antifungal stewardship programs for at-risk pediatric patients is crucial to enhance treatment outcomes, improve care, and prevent resistance development.
Article Abstract
Invasive fungal infections (IFIs) present significant challenges in managing hospitalized and immunocompromised pediatric patients, contributing to high morbidity and mortality. Despite advancements in diagnostics and treatment, outcomes remain suboptimal due to unique clinical epidemiology, lack of pediatric-specific trials, and varied pharmacokinetics. The emergence of new antifungal classes and agents has expanded our options for preventing and treating IFIs in children, enhancing the safety and effectiveness of antifungal therapy. The oral formulations of ibrexafungerp, fosmanogepix and olorofim along with the extended dosing intervals of rezafungin show promising features for effective antifungal treatment in pediatrics. Despite the promising potential of novel antifungal drugs, their performance in heavily immunosuppressed patients remains unstudied. Until then, dedicated antifungal stewardship programs for high-risk patients are essential to optimize therapeutic outcomes, improve patient care, and limit the emergence of resistance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11046-024-00896-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!